Beyond amyloid: the future of therapeutics for Alzheimer's disease.


Currently, the field is awaiting the results of several pivotal Phase III clinical Alzheimer's disease (AD) trials that target amyloid-β (Aβ). In light of the recent biomarker studies that indicate Aβ levels are at their most dynamic 5-10 years before the onset of clinical symptoms, it is becoming uncertain whether direct approaches to target Aβ will… (More)
DOI: 10.1016/B978-0-12-394816-8.00007-6


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics